
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp. has demonstrated strong growth in its HEPLISAV-B sales, achieving $71.1 million in 4Q24, which reflects a 39% year-over-year increase, and an overall annual sales figure of $268.4 million for FY24, a 26% increase. The company is well-positioned to capitalize on the expanding hepatitis B vaccination market, projected to exceed $900 million by 2030, with expectations for HEPLISAV-B to secure at least a 60% market share and continue to experience double-digit annual growth rates. Additionally, Dynavax's intention to implement a $400 million share repurchase program underscores its confidence in the company's financial health and future performance.
Bears say
Dynavax Technologies faces significant risks that contribute to a negative outlook for its stock, including the potential failure of its clinical candidates to meet efficacy and safety standards, which could hinder regulatory approval and commercialization. Additionally, the company may struggle to effectively market its products due to competitive pressures, potential litigation risks, and challenges in securing acceptable partnership agreements for its pipeline candidates. Financially, Dynavax has shown a pattern of losses and has not established a consistent profitability track record, as evidenced by its fourth-quarter 2024 revenue and earnings per share figures, which, although slightly above estimates, indicate ongoing financial vulnerabilities.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares